Personalis, Inc. - Common Stock (NQ:PSNL)

8.200 +0.785 (+10.59%)

Streaming Delayed Price Updated: 12:17 PM EST, Feb 6, 2026 Add to My Watchlist

Price and Volume

Volume	659,673
Open	7.850
Bid (Size)	8.190 (1,200)
Ask (Size)	8.220 (600)
Prev. Close	7.415
Today's Range	7.581 - 8.205
52wk Range	2.826 - 11.50
Shares Outstanding	48,518,901
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

AIGH Capital Dumps 2.6 Million Lumen Technologies Shares In $15.6 Million Exit ↗

February 03, 2026

This telecom provider delivers fiber, cloud, and security services to businesses and consumers across U.S. and international markets.

Via The Motley Fool

AIGH Capital Dumps 1.1 Million MaxLinear (MXL) Shares ↗

February 02, 2026

This semiconductor company provides integrated RF and mixed-signal solutions for broadband, wireless, and industrial connectivity.

Via The Motley Fool

Performance

YTD	+4.5%	+4.5%
1 Month	-10.4%	-10.4%
3 Month	+14.1%	+14.1%
6 Month	+80.4%	+80.4%
1 Year	+53.8%	+53.8%

More News

Personalis Announces New Publication Expanding Evidence for Ultrasensitive ctDNA Monitoring of Cancer Immunotherapy Response Across Solid Tumors

February 02, 2026

From Personalis, Inc.

Via Business Wire

Earnings Scheduled For November 4, 2025 ↗

November 04, 2025

Via Benzinga

Personalis to Participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference

January 28, 2026

From Personalis, Inc.

Via Business Wire

Personalis Pioneers Advancement in MRD Testing with the Launch of its Real-Time Variant Tracker™

January 12, 2026

From Personalis, Inc.

Via Business Wire

Personalis Reports Select Preliminary Fourth Quarter and Full Year 2025 Results and Recent Highlights

January 08, 2026

From Personalis, Inc.

Via Business Wire

Personalis Announces New Publication Applying Ultrasensitive ctDNA Testing to Monitoring Cancer Immunotherapy Response Across Solid Tumors

December 17, 2025

From Personalis, Inc.

Via Business Wire

New Publication Demonstrates the Importance of NeXT Personal Ultrasensitive Detection of Residual Disease in Lung Cancer

December 11, 2025

From Personalis, Inc.

Via Business Wire

Personalis to Participate in the Piper Sandler 37th Annual Healthcare Conference

November 18, 2025

From Personalis, Inc.

Via Business Wire

Let's uncover which stocks are experiencing notable gaps during today's session. ↗

November 10, 2025

Via Chartmill

Pagaya Technologies Posts Upbeat Q3 Results, Joins Ironwood Pharmaceuticals, TreeHouse Foods And Other Big Stocks Moving Higher On Monday ↗

November 10, 2025

Via Benzinga

Personalis Announces Medicare Coverage for Ultrasensitive MRD Test in Breast Cancer

November 10, 2025

From Personalis, Inc.

Via Business Wire

What's going on in today's after hours session ↗

November 04, 2025

Via Chartmill

Personalis Reports Third Quarter 2025 Financial Results

November 04, 2025

From Personalis, Inc.

Via Business Wire

Personalis to Announce Third Quarter 2025 Financial Results

October 21, 2025

From Personalis, Inc.

Via Business Wire

Personalis Announces New Data from a Landmark Lung Cancer Trial Utilizing Ultrasensitive MRD Testing

October 16, 2025

From Personalis, Inc.

Via Business Wire

Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 15, 2025

From Personalis, Inc.

Via Business Wire

CATE Clinical Trial Launched to Demonstrate the Clinical Utility of ctDNA-Guided Treatment in Breast Cancer Using the Ultrasensitive NeXT Personal Test

September 10, 2025

From Personalis, Inc.

Via Business Wire

Personalis Announces New Data from a Landmark Neoadjuvant Lung Cancer Trial Showing Superiority of Ultra-Sensitive, Tumor-Informed MRD Testing

September 03, 2025

From Personalis, Inc.

Via Business Wire

Personalis to Participate in Upcoming Investor Conferences

August 27, 2025

From Personalis, Inc.

Via Business Wire

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

August 06, 2025

Via Benzinga

The market is filled with gapping stocks in Wednesday's session. ↗

August 06, 2025

Via Chartmill

Discover the top movers in Wednesday's pre-market session. ↗

August 06, 2025

Via Chartmill

Super Micro Computer Posts Downbeat Q4 Results, Joins Personalis, Snap And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗

August 06, 2025

Via Benzinga

Frequently Asked Questions

Is Personalis, Inc. - Common Stock publicly traded?

Yes, Personalis, Inc. - Common Stock is publicly traded.

What exchange does Personalis, Inc. - Common Stock trade on?

Personalis, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Personalis, Inc. - Common Stock?

The ticker symbol for Personalis, Inc. - Common Stock is PSNL on the Nasdaq Stock Market

What is the current price of Personalis, Inc. - Common Stock?

The current price of Personalis, Inc. - Common Stock is 8.200

When was Personalis, Inc. - Common Stock last traded?

The last trade of Personalis, Inc. - Common Stock was at 02/06/26 12:17 PM ET

What is the market capitalization of Personalis, Inc. - Common Stock?

The market capitalization of Personalis, Inc. - Common Stock is 397.85M

How many shares of Personalis, Inc. - Common Stock are outstanding?

Personalis, Inc. - Common Stock has 398M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.